Regene4T secures investment from Neurotech Medical
The equity partnership gives Neurotech Medical exclusive handling rights over specified jointly developed research and preparations.
Neurotech Medical subscribed to a third-party share allotment by Regene4T. The January announcement did not disclose the amount or a named financing stage.
The companies plan to combine Regene4T’s neural-precursor extraction and nerve-function technologies with Neurotech Medical’s targeted nerve regeneration programme. Their agreement links the investment to joint research and commercial rights over resulting work.
Use of funds
Develop next-generation targeted nerve regeneration technology with Neurotech Medical